Please upgrade your browser.
The only renal cancer therapy proven to extend median overall survival compared with interferon-alpha in patients with advanced renal cell carcinoma (RCC).
In patients with advanced renal cell cancer, there was an overall response rate of 35 percent.
Drug firms Wyeth and Novartis AG each reported new uses for their respective cancer drugs at a medical conference Saturday.
When Richard Eckley was diagnosed with kidney cancer, doctors offered him an unenviable choice.
In renal cell and prostate cancer HIF-1α is degraded by Geldanamycin in both normoxia and hypoxia.
Dr. Robert Uzzo argued for observation in many renal masses.
In the future, kidney cancer is likely to be managed as a chronic disease.
Zometa when added to hormone therapy, following surgery, significantly reduced the risk of cancer returning or death by 36%
"This study is the first large-scale trial to demonstrate the significant antitumor benefit of zoledronic acid," said lead investigator Michael Gnant, M.D., of the Medical University of Vienna.
A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
"In the INTORACT study, we hope to learn more about whether combining TORISEL with other agents in the first-line setting may further improve outcomes for patients with this devastating disease."
The Templates can enhance patient safety by helping clinicians standardize patient care, reduce medication errors and anticipate and manage adverse events.
|Powered by NeonCRM|